LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Accueil・Liste d'Actions・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Fermé

SecteurSoins de santé

2.12 -0.47

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.02

Max

2.15

Chiffres clés
By Trading Economics
Revenu	14M -1M
Ventes	16M 21M
BPA	-0.003
Marge bénéficiaire	-4.943
Employés	81
EBITDA	14M -996K

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+88.32% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	240M 951M
Ouverture précédente	2.59
Clôture précédente	2.12

Sentiment de l'Actualité

By Acuity

41%

59%

134 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

0.6863 / 0.72 Support & Résistance

Lexicon Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 mai 2026, 20:36 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Résultats

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Résultats

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mai 2026, 22:02 UTC

Résultats

ZTO Express (Cayman): Di Xu to Resign From Board

19 mai 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mai 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mai 2026, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mai 2026, 21:37 UTC

Résultats

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mai 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mai 2026, 21:01 UTC

Résultats

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mai 2026, 20:58 UTC

Résultats

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mai 2026, 20:46 UTC

Actions en Tendance

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mai 2026, 20:34 UTC

Résultats

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries 4Q EPS 5c >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries 4Q Sales $1.4B >JHX

19 mai 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mai 2026, 20:03 UTC

Acquisitions, Fusions, Rachats

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mai 2026, 20:03 UTC

Acquisitions, Fusions, Rachats

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mai 2026, 20:02 UTC

Acquisitions, Fusions, Rachats

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mai 2026, 20:02 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparaison

Variation de prix

Lexicon Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

88.32% hausse

Prévisions sur 12 Mois

Moyen 4.03 USD 88.32%

Haut 6 USD

Bas 1 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

0.6863 / 0.72Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

134 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.